Investor Relations

Stock Data (click here)

SEC Filings (click here)

Press Releases (click here)

AIT Presentation (click here)

 

AIT Therapeutics Reports Financial Results for Fiscal Third Quarter 2019

Announced transformational partnership agreement with Circassia Pharmaceuticals
PMA filing for treatment of PPHN on track for second quarter calendar 2019
Completed treatment safely of a compassionate use NTM patient at 250 ppm nitric oxide
Strengthened team with appointment of Duncan Fatkin as Chief Commercial Officer
Added Bob Carey, a highly experienced industry veteran, to the Board of Directors
Submitted application to be listed on the NASDAQ stock exchange

Conference Call & Webcast

Wednesday, February 13th @ 4:30 pm Eastern Time
Domestic: 877-407-0784
International: 201-689-8560
Passcode: 13687310
Webcast: http://public.viavid.com/index.php?id=133178

Replays available through February 27th:
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 13687310

 

AIT Therapeutics Announces Appointment of Robert F. Carey to Board of Directors

“Bob is a seasoned healthcare executive and investment banking veteran with an impeccable track record and we are elated that he is joining the Board,” said Steve Lisi, Chairman and Chief Executive Officer of AIT. “His experience as the chief business officer at Horizon Pharma plc over the last five years and as an investment banker for more than two decades will be invaluable to the Board and our management team as AIT forges ahead with a planned launch in the United States of our AirNOvent* system with our commercial partner Circassia Pharmaceuticals, a pivotal study in bronchiolitis anticipated to read out in the second quarter of 2020, and an at-home pilot study in nontuberculous mycobacteria expected to commence by year-end 2019.”

 

AIT Therapeutics Schedules Fiscal Third Quarter 2019 Financial Results Conference Call and Webcast

AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, will report financial results for its fiscal third quarter ended December 31, 2018 after the market close on Wednesday, February 13, and will host a conference call and webcast at 4:30 pm Eastern Time.

Conference Call & Webcast

Wednesday, February 13th @ 4:30 pm Eastern Time
Domestic: 877-407-0784
International: 201-689-8560
Passcode: 13687310
Webcast: http://public.viavid.com/index.php?id=133178

Replays available through February 27th:
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 13687310

 

AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals

  • Milestone payment triggered by successful completion of a pre-submission meeting with the FDA
  • AIT has received $10.5 million to date in upfront and milestone payments
  • PMA submission on track for the second quarter of 2019

 

AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China

  • AIT to garner a 15%-20% royalty on gross profit
  • AIT will immediately request to be listed on the NASDAQ stock exchange
  • PMA submission on track for the second quarter of 2019
  • Company to host a call today, Thursday, January 24, 2019 at 8:30 am ET

 

AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer

 

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country

  • AIT to receive up to $32.5 million in up-front and regulatory milestones
  • Additionally, AIT to receive a 15%-20% royalty on annual gross profit
  • Partner to receive rights to all indications at nitric oxide concentrations < 80 ppm in the hospital setting
  • PMA submission on track for the second quarter of 2019

 

AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019 

  • PMA filing for treatment of PPHN expected in calendar second quarter 2019
  • Pivotal Bronchiolitis trial to initiate in calendar fourth quarter 2019 in the US
  • Positive clinical and pre-clinical data presented at several scientific conferences
  • Pilot “at-home” NTM trial to initiate in calendar 2019 in the US
  • Enhanced team with appointment of Douglas J. Beck as CFO and others in key operational areas

 

AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Webcast: http://wsw.com/webcast/canaccord32/aitb

 

AIT Therapeutics Schedules Fiscal Second Quarter 2019 Financial Results Conference Call and Webcast 

AIT Therapeutics Appoints Douglas J. Beck as Chief Financial Officer

AIT Therapeutics Presented Its High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

AIT Therapeutics to Present at the Ladenburg 4th Annual Healthcare Conference

AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

AIT Therapeutics Announces $526,500 Sale of Common Stock To Institutional Investor, Lincoln Park Capital Fund

AIT Therapeutics to Present Nitric Oxide Data at Two Upcoming Scientific Conferences

AIT Therapeutics Schedules Fiscal First Quarter 2019 Financial Results Conference Call and Webcast

AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference

AIT Therapeutics Announces Change to Fiscal Year End and Financial Results Conference Call and Webcast for the Three Months Ended March 31, 2018

AIT Therapeutics Presented Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex (MABSC) at the 2018 American Thoracic Society Conference

AIT Therapeutics Reports Year End 2017 Financial ResultsAIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast – March 19, 2018

AIT Therapeutics to Present at Two Investor Conferences 30th Annual ROTH Conference – March 12, 2018 and Oppenheimer 28th Annual Healthcare Conference – March 20, 2018

AIT Therapeutics to Hold Clinical Update Meeting – November 28, 2017 at 7:30 am ET

AIT Therapeutics Reports Third Quarter 2017 Financial Results Conference call / webcast for investors – November 3, 2017 at 10:30 am ET

AIT Therapeutics webcast for the Ladenburg Thalmann 2017 Healthcare Conference Conference call / webcast – September 26, 2017 at 4:00 pm ET; webcast will be archived for 365 days following the live presentation: http://wsw.com/webcast/ladenburg3/aitb/

AIT Therapeutics Reports Second Quarter 2017 Financial Results Conference call / webcast – August 11th, 2017 at 10:30 am ET

 

For Investor Relations enquiry, please email IR[at]ait-pharm.com, for Business Development and other matters, email BD[at]ait-pharm.com